---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056507"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:25:43.042307+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q3 net loss $24.6M; cash $385M; acquired ScalmiBio

## Summary
- GAAP net loss $24.6M ($0.61/sh) vs $10.8M ($0.36/sh) in Q3 2020; non-GAAP loss $20.4M.
- R&D expenses $18.2M, up from $5.3M, driven by higher clinical costs and stock-based comp.
- Cash and equivalents $385.1M; runway projected through 2024.
- Acquired ScalmiBio Oct 2021 for ~$4.5M upfront + $2M milestone and royalties; gains SHIELD ADC platform.
- Dosed first patients in ASPEN-05 (AML) and Zymeworks combo trial; ASH/SITC data presented or pending.

## SEC filing metadata
- accession: 0001564590-21-056507
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000156459021056507/0001564590-21-056507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000156459021056507/alxo-8k_20211111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056507
- JSON: https://secwatch.observer/filing/0001564590-21-056507.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.